Tumor News and Research

RSS

Positive results from nimotuzumab Phase II study for gastric cancer

YM BioSciences, a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, today announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea.

21 Jan 2011

ACT Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer

ACT Biotech, a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today released data on additional analysis of the Phase 2 clinical trial of telatinib in patients with metastatic stomach cancer that further supports the highly-potent nature of the antiangiogenic agent.

21 Jan 2011

Scientists decipher genetic code for a pancreatic cancer type

Scientists at Johns Hopkins have deciphered the genetic code for a type of pancreatic cancer, called neuroendocrine or islet cell tumors. The work, described online in the Jan. 20 issue of Science Express, shows that patients whose tumors have certain coding "mistakes" live twice as long as those without them.

21 Jan 2011

New gene test can predict tumor spread in bladder cancer patients

Cancer scientists have designed the first molecular test to predict which bladder cancer patients may have cancer involvement in their lymph nodes at the time of surgery-which could help doctors determine which patients are good candidates for pre-surgical, or neo-adjuvant, chemotherapy.

21 Jan 2011

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

Researchers at the Johns Hopkins University School of Medicine have discovered that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels.

20 Jan 2011

Study demonstrates prognostic value of DiagnoCure's Previstage GCC Colorectal Cancer Staging Test

DiagnoCure Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering lab services, today announced positive initial results of a multi-center clinical study of 241 stage II colon cancer patients, a population categorized as low risk by traditional methods yet with an average recurrence rate of 20%.

20 Jan 2011

OSC and RINCH offer support to speed discovery techniques of childhood diseases

Worried about her high fever and severe abdominal pain, a young couple rushed their baby daughter to the emergency department of Nationwide Children's Hospital. Physicians there found a lump in her belly, and, after examining X-rays and blood work, confirmed the parents' worst fear: their 18-month-old little girl had neuroblastoma, a rare pediatric cancer that involves the adrenal glands.

20 Jan 2011

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011

Precision Therapeutics to present pancreatic cancer data at 2011 ASCO GI Symposium

Precision Therapeutics, will present pancreatic cancer data based on Precision's ChemoFx in-vitro chemosensitivity test at the 2011 American Society of Clinical Oncology GI Symposium, January 20-22 in San Francisco, California.

20 Jan 2011

Endothelial cells may play a role in controlling cancer behavior: New study

MIT scientists have discovered that cells lining the blood vessels secrete molecules that suppress tumor growth and keep cancer cells from invading other tissues, a finding that could lead to a new way to treat cancer.

20 Jan 2011

First group of patients 'graduate' from treatment at CDH Proton Center, A Procure Center

Two months after the opening of the CDH Proton Center, A ProCure Center, the first patients have "graduated" from their treatment surrounded by family, friends and staff. The group of graduating patients, whose tumors included prostate, brain and a non-cancerous tumor on the spinal cord, received proton therapy, an alternative to standard X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

20 Jan 2011

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Neogenix Oncology announced today that Dr. Luis Diaz of The Johns Hopkins University Hospital will present data from Ensituximab, the company's novel, therapeutic antibody to treat pancreatic and colorectal cancers. The presentation is scheduled at the American Society of Clinical Oncology (ASCO) 2011 Gastrointestinal Cancers Symposium to be held January 20-22, 2011 at the Moscone Center in San Francisco, CA, USA.

19 Jan 2011

Researchers create biyouyanagin compound library

Using chemical compounds found in a Japanese plant as a lead and the clever application of ultraviolet light, a Scripps Research Institute team has created a unique library of dozens of synthetic compounds to test for biomedical potential. Already, one of the compounds has shown great promise in inhibiting replication of HIV particles and fighting inflammation.

19 Jan 2011

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUS study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOLFOX standard chemotherapy.

19 Jan 2011

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

Researchers have identified how the hormones progesterone and estrogen interact to increase cell growth in normal mammary cells and mammary cancers, a novel finding that may explain why postmenopausal women receiving hormone replacement therapy with estrogen plus progestin are at increased risk of breast cancer.

19 Jan 2011

Time-lapse technique can show cellular-level changes within deep brain regions: Study

Changes within deep regions of the brain can now be visualized at the cellular level, based on research on mice, which was funded by the National Institutes of Health. Published Sunday in Nature Medicine, the study used a groundbreaking technique to explore cellular-level changes over a period of weeks within deep brain regions, providing a level of detail not possible with previously available methods.

19 Jan 2011

Diabetes increases risk of death in breast cancer patients

Breast cancer patients are nearly 50 percent more likely to die of any cause if they also have diabetes, according to a comprehensive review of research conducted by Johns Hopkins physicians.

18 Jan 2011

PAM50 test is now available to classify breast cancer subtypes

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced the availability of a new laboratory developed test designed to classify breast cancer into clinically significant molecular subtypes that are important for the management of the disease.

18 Jan 2011

BSD Medical sells MicroThermX Microwave System to Med-Italia Biomedica

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, today announced the sale and shipment of the MicroThermX Microwave System to Med-Italia Biomedica (Med-Italia), one of the largest interventional radiology/oncology distributors in Italy.

18 Jan 2011

New data on role of miR-34 tumor suppressor in preventing cancer stem cell development

Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today the publication of new data in the journal Nature Medicine describing the role of the tumor suppressor miRNA, miR-34, in preventing cancer stem cell development. The published results reveal that miR-34 is commonly down-regulated in prostate cancer stem cells and that this down-regulation is essential for cancer stem cell viability.

18 Jan 2011

Tumor News and Research

Positive results from nimotuzumab Phase II study for gastric cancer

ACT Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer

Scientists decipher genetic code for a pancreatic cancer type

New gene test can predict tumor spread in bladder cancer patients

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

Study demonstrates prognostic value of DiagnoCure's Previstage GCC Colorectal Cancer Staging Test

OSC and RINCH offer support to speed discovery techniques of childhood diseases

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Precision Therapeutics to present pancreatic cancer data at 2011 ASCO GI Symposium

Endothelial cells may play a role in controlling cancer behavior: New study

First group of patients 'graduate' from treatment at CDH Proton Center, A Procure Center

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Researchers create biyouyanagin compound library

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

Time-lapse technique can show cellular-level changes within deep brain regions: Study

Diabetes increases risk of death in breast cancer patients

PAM50 test is now available to classify breast cancer subtypes

BSD Medical sells MicroThermX Microwave System to Med-Italia Biomedica

New data on role of miR-34 tumor suppressor in preventing cancer stem cell development

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News